Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Surgical Sutures Market Size & Share 2026-2035
Report ID: GMI14254
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Surgical Sutures Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Surgical Sutures Market Size
The global surgical sutures market was valued at USD 4.8 billion in 2025, is projected to reach USD 5.12 billion in 2026, and is expected to advance at approximately 6.5% CAGR (2026–2035) to USD 8.98 billion by 2035.
Surgical Sutures Market Key Takeaways
Market Leader: Ethicon (J&J MedTech) led with over 30.0% market share in 2025.
Leading Players: Top 5 players in this market include Ethicon (J&J MedTech), B. Braun Melsungen, Peters Surgical, Medtronic, Smith & Nephew, which collectively held a market share of 57.0% in 2025.
The market encompasses absorbable and non-absorbable surgical thread products across material types, needle configurations, and packaging formats purchased by hospitals, ambulatory surgical centers (ASCs), and specialty clinics.
The Surgical Sutures Market is being shaped by procedure growth and a changing clinical mix rather than a single demand event. Higher-acuity interventions, minimally invasive techniques, and infection-prevention protocols increase the value placed on reliable tissue handling, predictable absorption, and procedure-specific closure systems. End-user purchasing also reflects the contrasting economics of hospital contracts, group purchasing organizations, and ambulatory procurement.
GMI Analyst View
Our discussions with hospital procurement and surgical supply professionals across North America and Europe indicate that the global surgical sutures market stood at USD 4.10 billion in 2022. We view the subsequent demand profile as increasingly differentiated: institutional buyers are assigning greater value to product consistency, infection-risk management, and procedural efficiency, while maintaining rigorous scrutiny of closure costs.
Surgical Sutures Market Trends, Growth Drivers & GMI Forecast Outlook
The forecast outlook rests on a widening surgical procedure base and a gradual move toward clinically differentiated closure products. Demand conditions are favorable where hospitals can attach value to infection prevention and operating-room efficiency, while reimbursement pressure constrains value realization in fast-growing ambulatory channels.
Key Drivers
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*
Procedure growth is the fundamental volume lever for sutures because tissue approximation, ligation, and wound closure remain recurring consumable requirements across surgical specialties. The commercial effect is strongest when procedure expansion reaches facilities with deeper operating-room capability, where surgeons can specify material, needle, coating, and handling characteristics rather than rely on a narrow standardized formulary.
Demographic aging changes not only the number of surgical encounters but also the clinical demands attached to them. Patients with more complex comorbidities often require reliable tensile performance, carefully managed tissue response, and stronger infection-control practices, creating a favorable setting for differentiated absorbable and cardiovascular-oriented product selections.
Antimicrobial and knotless systems gain relevance when hospitals measure closure decisions against postoperative outcomes and operating-room workflow. Robotic and laparoscopic procedures reinforce this dynamic because intracorporeal knot tying can be technically demanding, making reliable barbed or advanced absorbable constructions more commercially meaningful than standard commodity alternatives.
Key Restraints
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*
ASC economics place cost-per-case considerations at the center of procurement decisions. This can favor standardized absorbable and non-absorbable products even when advanced alternatives offer workflow or infection-control benefits. Manufacturers therefore face a channel-specific trade-off between unit growth and realized pricing.
The migration of complex orthopaedic procedures into outpatient settings intensifies that tension. Per-case clinical demand does not disappear when surgery moves from a hospital to an ASC, but the purchasing environment becomes more sensitive to formulary price, supply consistency, and contract terms. Channel mix consequently matters as much as procedure count in assessing revenue performance.
Novel formulations face a more uncertain regulatory route than established material classes with recognizable predicate devices. For manufacturers, the burden is not limited to clearance timing; it also includes evidence generation, market-by-market registration, and the ability to support adoption after approval.
GMI Analyst View
We see a widening distinction between volume growth and value growth. Hospital systems can justify clinically differentiated closure products when infection prevention and operating-room performance are embedded in purchasing criteria, whereas ambulatory buyers prioritize dependable supply and disciplined case economics. Companies able to align portfolios and contracting models to both settings are better positioned than suppliers pursuing a single premiumization strategy.
Surgical Sutures Market Segment Analysis
By Product Type
Absorbable sutures generated USD 2.97 billion in 2025 and are expected to account for 66.0% of the global surgical sutures market revenue by 2035. Absorbable products benefit from broad clinical preference for materials that provide temporary tissue support and avoid the need for removal in many internal applications. Their commercial position is reinforced by product innovation in synthetic, antibacterial-coated, and knotless formats.
Non-absorbable sutures represented 38.0% of revenue in 2025 and are projected to grow at 5.3% CAGR (2026–2035). Long-term support requirements preserve the role of non-absorbable materials in cardiovascular, ophthalmic, trauma, and selected structural closures. The category remains clinically necessary, even as faster-growing procedures increasingly favor absorbable alternatives for internal tissue layers.
Natural catgut sutures recorded USD 538 million in 2025 and are projected to decline at a -1.8% CAGR (2026–2035). Natural materials are losing relevance where predictable absorption, tensile retention, and low tissue reactivity are priorities. Remaining demand is concentrated in cost-sensitive settings and established practice patterns rather than new procedural adoption.
Synthetic absorbable sutures accounted for 50.8% of market revenue in 2025 and are projected to reach USD 5.48 billion by 2035. This sub-segment benefits from material consistency and its adaptability to coated, barbed, and procedure-specific designs. It is also well aligned with institutional efforts to standardize performance across high-volume surgical service lines.
Nylon/polyamide sutures generated USD 1.23 billion in 2025 and are projected to reach USD 2.07 billion by 2035. Nylon and polyamide retain a durable role in fine tissue approximation, skin closure, neurosurgery, and ophthalmic procedures. Their position is supported by established handling characteristics and clinical familiarity in applications where removal or durable support is expected.
Polypropylene and other non-absorbable materials represented 12.2% of market revenue in 2025 and are projected to account for 10.9% by 2035. Polypropylene, polyester, silk, and related materials remain important in specialized indications, particularly where permanent support or vascular performance is required. Their relative share pressure reflects expansion of synthetic absorbable materials into closures previously served by traditional non-absorbable options.
By Filament
Monofilament sutures generated USD 2.68 billion in 2025 and are expected to hold 58.0% of market share by 2035. Smooth passage through tissue, reduced bacterial wicking, and suitability for delicate closures support monofilament demand. The configuration is particularly well positioned in minimally invasive, cardiac, neurological, and ophthalmic procedures where precision and tissue handling are central.
Multifilament sutures represented 44.0% of revenue in 2025 and are projected to generate USD 3.77 billion by 2035. Braided products remain valued for handling and knot security in many general and high-tension applications. Their continued relevance reflects clinical preference diversity rather than a uniform transition toward a single filament architecture.
By Application
Orthopaedic applications generated USD 1.24 billion in 2025 and are projected to reach USD 2.33 billion by 2035. Joint reconstruction, ligament repair, tendon work, and multilayer closure make orthopaedics highly suture intensive on a per-procedure basis. The ongoing movement of selected procedures to outpatient settings expands demand but also increases the importance of channel-specific product and pricing strategies.
Other surgeries accounted for 32.0% of market revenue in 2025 and are expected to reach USD 2.87 billion by 2035. General, gastrointestinal, colorectal, urological, and bariatric procedures provide the broadest application base for sutures. Their diversity supports demand across material types and creates room for differentiated infection-control and tissue-approximation products.
Cardiac applications generated USD 960 million in 2025 and are projected to grow at 7.5% CAGR (2026–2035). Cardiac surgery places a premium on dependable handling, secure anastomosis, and consistent material performance. Population aging and broader access to cardiovascular intervention support a favorable demand environment for specialized closure systems.
Gynaecology applications are projected to reach USD 898 million by 2035 and represented 11.0% of market revenue in 2025. Caesarean deliveries, hysterectomy procedures, and laparoscopic interventions create a broad base of suture use. The adoption of knotless systems in selected minimally invasive procedures can improve workflow while preserving the need for clinically appropriate closure selection.
Ophthalmic applications generated USD 288 million in 2025 and are projected to grow at 4.5% CAGR (2026–2035). Ophthalmic surgery requires fine-gauge products with controlled handling and minimal tissue response. Procedure innovation may moderate demand in some cataract closures, but specialized repair and microsurgical applications retain a stable need for precision sutures.
Neurological applications represented 5.0% of market revenue in 2025 and are projected to reach USD 449 million by 2035. Dural closure, nerve repair, and other neurological procedures require exacting tissue interaction and fine-caliber construction. This favors suppliers that can provide reliable monofilament options and support surgeon-specific preferences.
By End Use
Hospitals generated USD 3.12 billion in 2025 and are projected to account for 59.0% of market revenue by 2035. Hospitals concentrate complex and high-acuity procedures, making them the principal setting for broad suture portfolios and advanced configurations. Group purchasing contracts and quality-improvement programs can also make it easier to evaluate differentiated products on clinical and operational value.
ASCs are projected to reach USD 2.24 billion by 2035 and expand at 8.9% CAGR (2026–2035). The ASC channel benefits from procedure migration and high operating-room throughput, especially in orthopaedics and ophthalmology. Its purchasing model, however, rewards suppliers that can pair reliable product performance with disciplined case economics.
Specialty clinics accounted for 12.0% of market revenue in 2025 and are projected to reach USD 1.16 billion by 2035. Dermatology, plastic surgery, ophthalmology, and reproductive medicine practices support demand for application-specific closure solutions. These settings can be responsive to handling, cosmetic outcomes, and surgeon preference, but purchasing volumes are generally more fragmented than in hospital systems.
Other end-use settings remain a limited but relevant source of demand, including academic, field medical, and veterinary-adjacent facilities.
GMI Analyst View
We believe segmentation is increasingly determined by the clinical problem a suture solves rather than by material classification alone. Synthetic absorbable, monofilament, and advanced knotless platforms benefit when providers focus on predictable performance and workflow. Suppliers that connect material science to specific procedures, rather than selling a broad undifferentiated catalogue, should be better able to defend mix and margin.
Surgical Sutures Market Regional Analysis
North America Surgical Sutures Market Analysis
North America generated USD 1.68 billion in surgical sutures market revenue in 2025 and is projected to grow at 5.5% CAGR (2026–2035) The region combines high procedural intensity, sophisticated hospital procurement, and established clinical use of advanced closure systems. Maturity constrains volume acceleration relative to emerging regions, but infection prevention, robotic surgery, and hospital quality programs sustain demand for differentiated products.
U.S.
The U.S. generated USD 1.53 billion in 2025 and is projected to reach USD 2.63 billion by 2035. The U.S. market is shaped by a large ASC network, competitive hospital contracting, and broad regulatory support for medical-device commercialization. Suppliers must balance demand for premium hospital products with value-tier requirements in outpatient procurement.
Canada
Canada is projected to reach USD 247 million by 2035 and is expected to grow at 5.5% CAGR (2026–2035). Provincial procurement systems emphasize formulary discipline and cost control. Stable surgical demand, particularly in orthopaedic and cardiac care, supports recurring consumption, while premium adoption tends to depend on evidence and budget alignment.
Europe Surgical Sutures Market Analysis
Europe generated USD 1.29 billion in 2025 and is projected to reach USD 2.24 billion by 2035. An aging patient population, developed surgical infrastructure, and institutional attention to infection prevention support regional demand. The Medical Device Regulation increases compliance demands but can reinforce the position of manufacturers with established clinical and quality systems.
Germany
Germany generated USD 265 million in 2025 and is projected to reach USD 457 million by 2035. Germany's tertiary-care infrastructure, high procedural activity, and infection-control focus support both volume and premium suture demand. The market also offers a favorable setting for suppliers with strong clinical support and direct relationships with hospital buyers.
UK
The UK represented 16.5% of European revenue in 2025 and is projected to reach USD 369 million by 2035. National Health Service procurement and clinical guidance make evidence generation especially important to commercial access. Regulatory transition requirements can add administrative complexity, but they do not alter the underlying need for reliable, standardized surgical closure products.
France
France generated USD 191 million in 2025 and is projected to grow at 5.6% CAGR (2026–2035). Public hospitals and private clinics operate through distinct purchasing routes, requiring tailored commercial approaches. Domestic manufacturing presence and hospital-group relationships remain relevant to supplier positioning.
Italy
Italy represented 12.8% of European revenue in 2025 and is projected to reach USD 286 million by 2035. An older demographic profile underpins demand in orthopaedic and cardiovascular procedures. Regional health-authority purchasing creates opportunities for volume-based contracts but can limit rapid price expansion for premium products.
Spain
Spain generated USD 143 million in 2025 and is projected to grow at 5.6% CAGR (2026–2035). Evidence-based procurement and growing use of infection-control protocols support measured adoption of differentiated sutures. Private-hospital expansion provides an additional route for products with clear procedural or clinical value.
Netherlands
The Netherlands represented 5.9% of European revenue in 2025 and is projected to reach USD 133 million by 2035. Academic hospital networks and evidence-led purchasing support early use of clinically differentiated surgical products. The market's smaller scale makes focused institutional access more important than broad distribution alone.
Asia Pacific Surgical Sutures Market Analysis
Asia Pacific is projected to grow at 8.2% CAGR (2026–2035) and reach USD 2.96 billion by 2035. Asia Pacific is the principal regional growth engine, but it is not a uniform market. Manufacturers must adapt to price-focused procurement in China, high clinical sophistication in Japan and South Korea, and rapidly expanding surgical access in India and other developing healthcare systems.
China
China generated USD 470 million in 2025 and is projected to grow at 9.5% CAGR (2026–2035). Volume-based procurement exerts substantial pricing pressure on standardized categories while leaving room for specialized products outside tightly controlled purchasing scopes. Success depends on local market access, manufacturing economics, and clear differentiation in advanced applications.
Japan
Japan generated USD 336 million in 2025 and is projected to grow at 3.5% CAGR (2026–2035). Japan combines sophisticated surgical practice and a highly aged population with reimbursement policies that constrain price realization. Suppliers must demonstrate clinical relevance within a market where procedure growth is more mature and buying decisions are tightly structured.
India
India is projected to grow at 12.0% CAGR (2026–2035) and reach USD 627 million by 2035. Expanding coverage, hospital capacity, and private surgical networks are broadening access to procedures. The opportunity favors manufacturers that combine scalable distribution with products suited to a wide range of price points and care settings.
South Korea
South Korea represented 10.0% of Asia Pacific revenue in 2025 and is projected to reach USD 251 million by 2035. A technologically advanced hospital base and strong uptake of robotic surgery support demand for precision and knotless configurations. Aging-related surgical need further supports specialized product selection.
Australia
Australia generated USD 94 million in 2025 and is projected to grow at 4.5% CAGR (2026–2035). A well-developed specialist and private-care environment supports use of premium suture products. Its relatively limited scale means commercial success depends on focused account access and portfolio fit rather than volume alone.
Latin America Surgical Sutures Market Analysis
Latin America represented 7.0% of global market revenue in 2025 and is projected to reach USD 628 million by 2035. Growth is led by the region's larger healthcare markets, where expanding procedure volumes meet uneven reimbursement and regulatory conditions. Manufacturers need flexible pricing, dependable distribution, and an ability to serve both public tenders and private providers.
Brazil
Brazil generated USD 168 million in 2025 and is projected to grow at 6.4% CAGR (2026–2035). Brazil combines cost-conscious public procurement with a developing private-hospital market that is more receptive to differentiated products. The balance between these channels shapes both product mix and competitive access.
Mexico
Mexico represented 30.1% of Latin American revenue in 2025 and is projected to reach USD 189 million by 2035. Public-sector purchasing drives baseline demand for value-oriented sutures, while private specialist facilities create opportunities in more complex procedures. Commercial approaches must therefore reconcile centralized procurement with localized premium demand.
Argentina
Argentina generated USD 34 million in 2025 and is projected to grow at 6.5% CAGR (2026–2035). Macroeconomic and foreign-exchange pressures complicate pricing for international suppliers. Nonetheless, established clinical capability and broad healthcare access sustain procedure-related demand.
Middle East & Africa Surgical Sutures Market Analysis
The Middle East & Africa generated USD 144 million in 2025 and is projected to grow at 6.5% CAGR (2026–2035). Regional demand is split between infrastructure investment in Gulf markets and capacity-constrained health systems elsewhere. Distribution capability, registration expertise, and tender participation are often as important as product differentiation in determining market access.
Saudi Arabia
Saudi Arabia generated USD 49 million in 2025 and is projected to grow at 6.5% CAGR (2026–2035). Healthcare privatization and capacity expansion are widening procurement routes beyond traditional public tenders. Demand from bariatric and orthopaedic procedures supports an attractive setting for suppliers with strong local market development capabilities.
UAE
The UAE represented 25.0% of Middle East & Africa revenue in 2025 and is projected to reach USD 68 million by 2035. Premium private hospitals and medical-tourism activity support demand for branded, specialized surgical products. Suppliers can differentiate through clinical support, product availability, and relationships with high-acuity facilities.
South Africa
South Africa generated USD 23 million in 2025 and is projected to grow at 6.4% CAGR (2026–2035). The country's dual public-private healthcare system creates differentiated demand profiles. International branded products are more viable in private care, while public procurement emphasizes cost competitiveness and supply reliability.
GMI Analyst View
We assess regional opportunity through the interaction of procedure access, purchasing architecture, and product differentiation. Mature markets reward suppliers that can defend hospital relationships and articulate clinical value, while high-growth markets require localized pricing, registration, and distribution capabilities. A uniform global route-to-market is unlikely to capture the full potential of this market.
Surgical Sutures Market Share & Competitive Landscape
The Surgical Sutures Market share structure was moderately concentrated in 2025, with the five leading suppliers collectively accounting for 57.0% of revenue. Scale matters because leading participants can support broad portfolios, hospital contracts, regulatory compliance, and clinical education, while regional and specialty manufacturers retain opportunities in focused applications and price-sensitive markets.
Ethicon, part of Johnson & Johnson MedTech, held a 30.0% market share in 2025. Its position is supported by a broad portfolio spanning absorbable, non-absorbable, antibacterial, and knotless systems, allowing the company to compete across hospital and ambulatory accounts while addressing varied surgical-specialty requirements.
B. Braun Melsungen held a 12.0% market share in 2025. Its established European hospital footprint and product breadth support competitive strength in settings where quality systems, clinical familiarity, and procurement relationships influence supplier selection.
Peters Surgical held a 6.0% market share in 2025. Its integration into Advanced Medical Solutions strengthens the combined organization's tissue-repair and closure offering, creating potential commercial leverage through complementary product lines and direct distribution capabilities.
Medtronic held a 5.0% market share in 2025. Its wound-closure portfolio benefits from the company's broad hospital relationships and adjacency to surgical technologies, providing cross-selling potential in accounts that seek consolidated purchasing and clinical support.
Smith & Nephew held a 4.0% market share in 2025. Its orthopaedic and sports-medicine positioning gives it access to procedure areas where suture performance is closely connected to reconstruction and soft-tissue repair requirements.
Competitive intensity is increasing through portfolio renewal, targeted acquisitions, and investment in specialized applications. Advanced Medical Solutions is expanding its wound-closure capabilities through Peters Surgical, while Corza Medical is building further ophthalmic depth. Healthium Medtech, Dolphin Sutures, GPC Medical, and Kono Seisakusho contribute regional and price-segment competition, while Stryker, Zimmer Biomet, Boston Scientific, Integra LifeSciences, CONMED, and Teleflex compete in procedure-adjacent areas that can influence closure-product choice.
Recent Industry Developments
May 2026 - Ethicon (Johnson & Johnson MedTech): The FDA cleared the STRATAFIX Symmetric PDS Plus Knotless Tissue Control Device for soft-tissue approximation, including high-tension surgical applications. The antibacterial, barbed absorbable device expands Ethicon's knotless closure platform for procedures where operating-room efficiency and secure tissue approximation are commercially important [5]U.S. Food and Drug Administration / Medtronic / Covidien. “510(k) Premarket Notification K253530 — Trexon™ Monofilament Synthetic Absorbable Suture.” accessdata.fda.gov.
May 2026 - Medtronic: The FDA cleared Trexon Monofilament Synthetic Absorbable Suture for soft-tissue approximation. The development reinforces Medtronic's continued investment in the synthetic absorbable category within its wound-closure portfolio .
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →